» Articles » PMID: 37940688

A Prognostic Model for Ovarian Neoplasms Established by an Integrated analysis of 1580 Transcriptomic Profiles

Overview
Journal Sci Rep
Specialty Science
Date 2023 Nov 8
PMID 37940688
Authors
Affiliations
Soon will be listed here.
Abstract

Even after debulking surgery combined with chemotherapy or new adjuvant chemotherapy paired with internal surgery, the average year of disease free survival in advanced ovarian cancer was approximately 1.7 years. The development of a molecular predictor of early recurrence would allow for the identification of ovarian cancer (OC) patients with high risk of relapse. The Ovarian Cancer Disease Free Survival Predictor (ODFSP), a predictive model constructed from a special set of 1580 OC tumors in which gene expression was assessed using both microarray and sequencing platforms, was created by our team. To construct gene expression barcodes that were resistant to biases caused by disparate profiling platforms and batch effects, we employed a meta-analysis methodology that was based on the binary gene pair technique. We demonstrate that ODFSP is a reliable single-sample predictor of early recurrence (1 year or less) using the largest pool of OC transcriptome data sets available to date. The ODFSP model showed significantly high prognostic value for binary recurrence prediction unaffected by clinicopathologic factors, with a meta-estimate of the area under the receiver operating curve of 0.64 (P  =  4.6E-05) and a D-index (robust hazard ratio) of 1.67 (P  =  9.2E-06), respectively. GO analysis of ODFSP's 2040 gene pairs (collapsed to 886 distinct genes) revealed the involvement in small molecular catabolic process, sulfur compound metabolic process, organic acid catabolic process, sulfur compound biosynthetic process, glycosaminoglycan metabolic process and aminometabolic process. Kyoto encyclopedia of genes and genomes pathway analysis of ODFSP's signature genes identified prominent pathways that included cAMP signaling pathway and FoxO signaling pathway. By identifying individuals who might benefit from a more aggressive treatment plan or enrolment in a clinical trial but who will not benefit from standard surgery or chemotherapy, ODFSP could help with treatment decisions.

Citing Articles

Is There a Correlation Between Platelet Count, Mesenteric Lymph Node Involvement, and Hematogenous Metastases in Advanced Stage Ovarian Cancer?.

Bacalbasa N, Petrea S, Gaspar B, Pop L, Varlas V, Hasegan A In Vivo. 2024; 38(6):2945-2954.

PMID: 39477394 PMC: 11535961. DOI: 10.21873/invivo.13777.

References
1.
Palmqvist C, Staf C, Mateoiu C, Johansson M, Albertsson P, Dahm-Kahler P . Increased disease-free and relative survival in advanced ovarian cancer after centralized primary treatment. Gynecol Oncol. 2020; 159(2):409-417. DOI: 10.1016/j.ygyno.2020.09.004. View

2.
Afsari B, Fertig E, Geman D, Marchionni L . switchBox: an R package for k-Top Scoring Pairs classifier development. Bioinformatics. 2014; 31(2):273-4. PMC: 4287945. DOI: 10.1093/bioinformatics/btu622. View

3.
Feng L, Li L . Low expression of NCALD is associated with chemotherapy resistance and poor prognosis in epithelial ovarian cancer. J Ovarian Res. 2020; 13(1):35. PMC: 7106630. DOI: 10.1186/s13048-020-00635-6. View

4.
Sallinen H, Janhonen S, Polonen P, Niskanen H, Liu O, Kivela A . Comparative transcriptome analysis of matched primary and distant metastatic ovarian carcinoma. BMC Cancer. 2019; 19(1):1121. PMC: 6862850. DOI: 10.1186/s12885-019-6339-0. View

5.
van der Ploeg P, Uittenboogaard A, Bosch S, van Diest P, Wesseling-Rozendaal Y, van de Stolpe A . Signal transduction pathway activity in high-grade serous carcinoma, its precursors and Fallopian tube epithelium. Gynecol Oncol. 2022; 165(1):114-120. DOI: 10.1016/j.ygyno.2022.01.027. View